Strategies to enhance the racial and ethnic diversity of breast cancer clinical drug trials
This research addresses the critical issue of underrepresentation of racial and ethnic minorities in breast cancer clinical trials. Despite breast cancer being the most diagnosed cancer globally among women, with significant disparities in outcomes among ethnic minorities - the diversity in clinical trials remains insufficient. The authors conducted a rapid review to identify and evaluate strategies aimed at improving ethnic diversity in these trials. The findings highlight the importance of implementing targeted recruitment strategies, enhancing community engagement, and addressing systemic barriers to participation.
- Recognise the current disparities in breast cancer incidence and outcomes among racial and ethnic groups
- Understand the ethical, scientific, and clinical implications of a lack of diversity in trial populations
- Explain the key barriers that prevent equitable participation of racial and ethnic minorities in breast cancer clinical research
- Understand the bespoke RMG model, and the 8 key strategic themes designed increase diversity in breast cancer clinical trials